Integral Investment Advisors Inc. Acquires Shares of 4,819 Moderna, Inc. (NASDAQ:MRNA)

Integral Investment Advisors Inc. acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 4,819 shares of the company’s stock, valued at approximately $200,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MRNA. Wilmington Savings Fund Society FSB lifted its holdings in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. Compass Planning Associates Inc purchased a new position in Moderna in the 4th quarter valued at $37,000. Venturi Wealth Management LLC lifted its holdings in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in Moderna by 53.1% in the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after purchasing an additional 388 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on MRNA shares. Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Evercore ISI set a $50.00 target price on Moderna in a research note on Friday, February 14th. Berenberg Bank raised their target price on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday, January 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $69.00 target price (down from $115.00) on shares of Moderna in a research note on Monday, November 18th. Finally, Bank of America cut their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday, February 11th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $60.63.

Moderna Stock Performance

Shares of MRNA opened at $35.53 on Friday. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The stock has a 50-day simple moving average of $38.04 and a 200-day simple moving average of $52.66. The stock has a market capitalization of $13.67 billion, a PE ratio of -3.83 and a beta of 1.59.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is owned by insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.